nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.12.2011 | Review

BCG response prediction with cytokine gene variants and bladder cancer: where we are?

verfasst von: Dinesh Kumar Ahirwar, Parmeet Kaur Manchanda, Rama Devi Mittal, Hemant K. Bid

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Bladder cancer (BC) is one of the most widespread cancers afflicting men and women and also has major philosophical impact on health care worldwide. Despite elaborate characterization of the risk factors and treatment options, BC is still a major epidemiological problem worldwide and its incidence lingers to upswing each year. Over the last three decades, intravesical immunotherapy with the biological response modifier Mycobacterium bovis–Bacillus Calmette Guerin (BCG) has been established as the most effective adjuvant treatment for averting local recurrences and tumor progression following transurethral resection of non-muscle-invasive bladder cancer.

Design and methods

PUBMED database was searched for articles, and manuscripts were selected that provided data regarding the correlation of BCG therapy and its response with different cytokine gene variants.

Results

It is not clear how Bacillus Calmette-Guerin (BCG) works to treat BC. It may stimulate an immune response or cause inflammation of the bladder wall that destroys cancer cells within the bladder. Lot of reports indicated the correlation of various cytokines with respect to BCG therapy in BC, but the exact mechanism is under debate.

Conclusion

Research continues to establish the most effectual strain of BCG and the best dosage schedule for the treatment for bladder cancer but, on the other hand, a very critical part of this therapy to find out the correlation of different cytokine with BCG therapy, which will give a better insights not only the mechanism but also a better therapeutic options.

Agarwal A, Agrawal U, Verma S, Mohanty NK, Saxena S (2010) Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacol Immunotoxicol 32(2):348–356PubMedCrossRef

Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S (2006) Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother 55:734–743PubMedCrossRef

Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD (2008) Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and Bacillus Calmette-Guerin immunotherapy in bladder cancer. Cancer Genet Cytogenet 184:1–8PubMedCrossRef

Ahirwar DK, Agrahari A, Mandhani A, Mittal RD (2009a) Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers 14:213–218PubMedCrossRef

Ahirwar D, Mandhani A, Mittal RD (2009b) Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer. Arch Med Res 40:97–102PubMedCrossRef

Apte RN, Dotan S, Elkabets M et al (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25:387–408PubMedCrossRef

Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16:27–55PubMedCrossRef

Aulitzky WE, Huber C, Peschel C (1993) Cytokine therapy of neoplastic and inflammatory disease. Int Arch Allergy Immunol 101:221–226PubMedCrossRef

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRef

Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211–217PubMedCrossRef

Bedwani R, Renganathan E, El Kwhsky F et al (1998) Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Br J Cancer 77:1186–1189PubMedCrossRef

Bevers RF, de Boer EC, Kurth KH, Schamhart DH (1998) BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur Cytokine Netw 9(2):181–186

Bid HK, Manchanda PK, Mittal RD (2006) Association of interleukin-1Ra gene polymorphism in patients with bladder cancer: case control study from North India. Urology 67:1099–1104PubMedCrossRef

Bidwell J, Keen L, Gallagher G et al (2001) Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun 2:61–70PubMedCrossRef

Black PC, Dinney CP (2007) Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev 26:623–634PubMedCrossRef

Boehm U, Klamp T, Groot M, Howard JC (1997) Cellular responses to interferon-gamma. Annu Rev Immunol 15:749–795PubMedCrossRef

Bohle A, Brandau S (2003) Immune mechanisms in Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170:964–969PubMedCrossRef

Bohle A, Nowc C, Ulmer AJ et al (1990) Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma. Cytokine 2:175–181PubMedCrossRef

Burke F, Relf M, Negus R, Balkwill F (1996) A cytokine profile of normal and malignant ovary. Cytokine 8:578–585PubMedCrossRef

Cardillo MR, Sale P, Di Silverio F (2000) Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res 20:4579–4583PubMed

Castillejo A, Rothman N, Murta-Nascimento C et al (2009) TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer 124:608–613PubMedCrossRef

Chandler SW, Rassekh CH, Rodman SM, Ducatman BS (2002) Immunohistochemical localization of interleukin-10 in human oral and pharyngeal carcinomas. Laryngoscope 112:808–815PubMedCrossRef

Chin JL, Kadhim SA, Batislam E et al (1996) Mycobacterium cell wall: an alternative to intravesical Bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol 156:1189–1193PubMedCrossRef

Conticello C, Pedini F, Zeuner A et al (2004) IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 172:5467–5477PubMed

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRef

Davis BN, Hilyard AC, Lagna G, Hata A (2008) SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454:56–61PubMedCrossRef

de Reijke TM, de Boer EC, Kurth KH, Schamhart DH (1996) Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 155:477–482PubMedCrossRef

de Visser KE, Kast WM (1999) Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 13:1188–1199PubMedCrossRef

Escudero-Lourdes C, Medeiros MK, Cárdenas-González MC, Wnek SM, Gandolfi JA (2010) Low level exposure to monomethyl arsonous acid-induced the over-production of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model. Toxicol Appl Pharmacol 244(2):162–173PubMedCrossRef

Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E (1993) Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 50:15–19PubMedCrossRef

Ganesan PL, Alexander SI, Watson D, Logan GJ, Zhang GY, Alexander IE (2007) Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression. Cancer Immunol Immunother 56:1955–1965PubMedCrossRef

Goldman M, Velu T (1995) Interleukin-10 and its implications for immunopathology. Adv Nephrol Necker Hosp 24:79–90PubMed

Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, Hamman RF (2002) Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil 83:346–351PubMedCrossRef

Hameed DA, El-Metwally TH (2008) The effectiveness of retinoic acid treatment in bladder cancer: impact on recurrence, survival and TGFalpha and VEGF as end-point biomarkers. Cancer Biol Ther 7:92–100PubMedCrossRef

Harlan DM, Kirk AD (1999) The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? JAMA 282:1076–1082PubMedCrossRef

Hawkyard SJ, Jackson AM, James K, Prescott S, Smyth JF, Chisholm GD (1992) The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol 147:1399–1403PubMed

Hussain SP, Hofseth LJ, Harris CC (2003) Radical causes of cancer. Nat Rev Cancer 3:276–285PubMedCrossRef

Inoue K, Slaton JW, Eve BY et al (2000) Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6:2104–2119PubMed

Jackson AM, Alexandroff AB, Kelly RW et al (1995) Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99:369–375PubMedCrossRef

Jaiswal M, LaRusso NF, Gores GJ (2001) Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 281:G626–G634PubMed

Kantor AF, Hartge P, Hoover RN, Narayana AS, Sullivan JW, Fraumeni JF Jr (1984) Urinary tract infection and risk of bladder cancer. Am J Epidemiol 119:510–515PubMed

Kawai K, Kawamata H, Kemeyama S, Rademaker A, Oyasu R (1994) Persistence of carcinogen-altered cell population in rat urothelium which can be promoted to tumors by chronic inflammatory stimulus. Cancer Res 54:2630–2632PubMed

Kelley DR, Ratliff TL, Catalona WJ et al (1985) Intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of Bacillus Calmette-Guerin viability on treatment results. J Urol 134:48–53PubMed

Kitamura H, Tsukamoto T (2011) Immunotherapy for urothelial carcinoma: current status and perspectives. Cancers 3:3055–3072CrossRef

Konwar R, Gara R, Singh M, Singh V, Chattopadhyay N, Bid HK (2008) Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology 71:868–872PubMedCrossRef

Konwar R, Chaudhary P, Kumar S, Mishra D, Chattopadhyay N, Bid HK (2009) Breast cancer risk associated with polymorphisms of IL-1RN and IL-4 gene in Indian women. Oncol Res 17:367–372PubMedCrossRef

Leibovici D, Grossman HB, Dinney CP et al (2005) Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23:5746–5756PubMedCrossRef

Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175–1183PubMedCrossRef

Lucey DR, Clerici M, Shearer GM (1996) Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9:532–562PubMed

Luo Y, Chen X, Downs TM, DeWolf WC, O’Donnell MA (1999) IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis Bacillus Calmette-Guerin immunotherapy. J Immunol 162:2399–2405PubMed

Luo Y, Han R, Evanoff DP, Chen X (2004) Interleukin-10 inhibits Mycobacterium bovis Bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. Clin Exp Immunol 160:359–368CrossRef

Margalit M, Shibolet O, Klein A et al (2005) Suppression of hepatocellular carcinoma by transplantation of ex vivo immune-modulated NKT lymphocytes. Int J Cancer 115:443–449PubMedCrossRef

Michaud DS (2007) Chronic inflammation and bladder cancer. Urol Oncol 25:260–268PubMedCrossRef

Miki S, Iwano M, Miki Y et al (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250:607–610PubMedCrossRef

Mitra AP, Cote RJ (2009) Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 4:251–285PubMedCrossRef

Mittal RD, Manchanda PK, Bid HK, Ghoshal UC (2007) Analysis of polymorphisms of tumor necrosis factor-alpha and polymorphic xenobiotic metabolizing enzymes in inflammatory bowel disease: study from northern India. J Gastroenterol Hepatol 22:920–924PubMedCrossRef

Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165–190PubMedCrossRef

Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765PubMedCrossRef

Okamoto M, Kawamata H, Kawai K, Oyasu R (1995) Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by interleukin 6. Cancer Res 55:4581–4585PubMed

Okamoto M, Kawai K, Reznikoff CA, Oyasu R (1996) Transformation in vitro of a nontumorigenic rat urothelial cell line by hydrogen peroxide. Cancer Res 56:4649–4653PubMed

Okamoto M, Lee C, Oyasu R (1997a) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57:141–146PubMed

Okamoto M, Hattori K, Oyasu R (1997b) Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 72:149–154PubMedCrossRef

Petit-Bertron AF, Pedron T, Gross U et al (2005) Adherence modifies the regulation of gene expression induced by interleukin-10. Cytokine 29:1–12PubMed

Pooja S, Francis A, Bid HK, Kumar S, Rajender S, Ramalingam K, Thangaraj K, Konwar R (2011) Role of ethnic variations in TNF-α and TNF-β polymorphisms and risk of breast cancer in India. Breast Cancer Res Treat 126(3):739–747

Ratliff TL, Kavoussi LR, Catalona WJ (1988) Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 139:410–414PubMed

Reay J, Kim SH, Lockhart E, Kolls J, Robbins PD (2009) Adenoviral-mediated, intratumor gene transfer of interleukin 23 induces a therapeutic antitumor response. Cancer Gene Ther 16:776–785PubMedCrossRef

Reznikoff CA, Sarkar S, Julicher KP et al (2000) Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol Oncol 5:191–203PubMedCrossRef

Sander B, Damm O, Gustafsson B, Andersson U, Hakansson L (1996) Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical Bacillus Calmette-Guerin. J Urol 156:536–541PubMedCrossRef

Schamhart DH, de Boer EC, de Reijke TM, Kurth K (2000) Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use. Eur Urol 37(Suppl 3):16–23PubMedCrossRef

Schmiegel W, Roeder C, Schmielau J, Rodeck U, Kalthoff H (1993) Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci USA 90:863–867PubMedCrossRef

Schwarzer K, Foerster M, Steiner T, Hermann IM, Straube E (2010) BCG strain S4-Jena: an early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis. Cancer Cell Int 10:21PubMedCrossRef

Seddighzadeh M, Larsson P, Ulfgren AC et al (2003) Low IL-1alpha expression in bladder cancer tissue and survival. Eur Urol 43:362–368PubMedCrossRef

Seguchi T, Yokokawa K, Sugao H, Nakano E, Sonoda T, Okuyama A (1992) Interleukin-6 activity in urine and serum in patients with bladder carcinoma. J Urol 148:791–794PubMed

Sethi G, Sung B, Aggarwal B (2008) TNF: a masterswitch for inflammation to cancer. Front Biosci 13:5094–5107PubMedCrossRef

Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guerin and its correlation with Bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res 43:1611–1615PubMed

Sharif-Afshar AR, Donohoe JM, Pope JCT, Adams MC, Brock JW III, Bhowmick NA (2005) Stromal hyperplasia in male bladders upon loss of transforming growth factor-beta signaling in fibroblasts. J Urol 174:1704–1707 (discussion 7)PubMedCrossRef

Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T (2007) Intravesical instillation therapy with Bacillus Calmette-Guerin for superficial bladder cancer: study of the mechanism of Bacillus Calmette-Guerin immunotherapy. Int J Urol 14:140–146PubMedCrossRef

Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3:807–821PubMedCrossRef

Sosroseno W, Herminajeng E, Goeno S (1994) The interleukin network in the immunopathogenesis of oral diseases. Asian Pac J Allergy Immunol 12:161–168PubMed

Stavropoulos NE, Ioachim E, Pappa L, Hastazeris K, Agnantis NJ (1999) Antiproliferative activity of interferon gamma in superficial bladder cancer. Anticancer Res 19:4529–4533PubMed

Stricker P, Pryor K, Nicholson T et al (1996) Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 48:957–961 (discussion 61–62)PubMedCrossRef

Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H (1999) Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 59:4516–4518PubMed

Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA, Weiss RM (1999) Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol 161:630–634PubMedCrossRef

Wojtowicz-Praga S (2003) Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 21:21–32PubMedCrossRef

Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12:311–320PubMedCrossRef

Yamamoto M, Wu HH, Momose H, Rademaker A, Oyasu R (1992) Marked enhancement of rat urinary bladder carcinogenesis by heat-killed Escherichia coli. Cancer Res 52:5329–5333PubMed

Zhang Y, Mahendran R, Yap LL, Esuvaranathan K, Khoo HE (2002) The signalling pathway for BCG-induced interleukin-6 production in human bladder cancer cells. Biochem Pharmacol 63:273–282PubMedCrossRef

Titel: BCG response prediction with cytokine gene variants and bladder cancer: where we are?
verfasst von: Dinesh Kumar Ahirwar
Parmeet Kaur Manchanda
Rama Devi Mittal
Hemant K. Bid
Publikationsdatum: 01.12.2011
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2011
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-1056-3

Springer Medizin

BCG response prediction with cytokine gene variants and bladder cancer: where we are?

Abstract

Purpose

Design and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Design and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2011

Molecular analysis of oncogenicity of the transcription factor, BRN3A, in cervical cancer cells

RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration

Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis

Expression and clinical significance of leptin, the functional receptor of leptin (OB-Rb) and HER-2 in non-small-cell lung cancer: a retrospective analysis

Interventional therapies of unresectable liver metastases

Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie